News Quantified

XERS – xeris biopharma holdings, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]

Xeris Biopharma (XERS) was upgraded by Weiss Ratings from "sell (d-)" to "hold (c-)".

Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio [Seeking Alpha]

Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]

Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]

-5.9%

BEAT

-15.3%

MISS

20.0%

BEAT

17.3%

BEAT

Form 4 Xeris Biopharma Holdings For: Mar 12 Filed by: McCulloch Kevin

Form 4 Xeris Biopharma Holdings For: Mar 05 Filed by: Pieper Steven

Form 4 Xeris Biopharma Holdings For: Mar 02 Filed by: Hecht Beth

Form 144 Xeris Biopharma Holdings Filed by: Hecht Beth

Form S-8 Xeris Biopharma Holdings

Top News Gainers

3/12 Form S-8 XERIS PHARMACEUTICALS 28.5%

4/29 Xeris Extends $0 Copay for Gvoke™ PFS For People With Diabetes Through May 31, 2020 24.4%

3/16 Form 4 XERIS PHARMACEUTICALS For: Mar 13 Filed by: Hecht Beth 14.0%

1/6 Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise 9.4%

4/24 Form DEF 14A XERIS PHARMACEUTICALS For: Dec 31 9.0%

2/14 Form SC 13G XERIS PHARMACEUTICALS Filed by: ArrowMark Colorado Holdings LLC 8.3%

4/3 Xeris Pharmaceuticals Inc (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $18.00 price target on the stock. 8.1%

2/18 Form 4 XERIS PHARMACEUTICALS For: Feb 14 Filed by: Deutsch Barry M. 7.9%

6/17 Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon 7.6%

5/9 Q1/2019 3/31/2019 EPS -1.070 ZacksConsensus N/A ActVsEst N/A - N/A 7.6%

Top News Decliners

2/10 Xeris Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of Common Stock -29.1%

3/11 Xeris Pharmaceuticals, Inc. (XERS) Q4 2019 Earnings Call Transcript [The Motley Fool] -19.7%

9/10 Xeris Pharma halted pending news [Seeking Alpha] -11.8%

3/26 Xeris Pharmaceuticals Announces $0 Copay for Gvoke™ PFS for People With Diabetes -10.1%

2/11 Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock -9.4%

1/6 Xeris Pharma stock rallies more than 20% on study results [MarketWatch] -9.4%

11/7 Q3/2019 9/30/2019 EPS -1.220 ZacksConsensus -1.260 ActVsEst 0.040 - Beat -7.7%

4/10 Form 8-K XERIS PHARMACEUTICALS For: Apr 10 -7.1%

3/2 Form 4 XERIS PHARMACEUTICALS For: Jan 31 Filed by: Shannon John Patrick Jr -7.0%

4/30 Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 -6.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day